Catalyst Pharmaceuticals Teams Up with Patients and Advocacy Groups to Ring Nasdaq Opening Bell on Rare Disease Day 2022
Ceremony Recognizes Importance of Biopharma Industry and Advocacy Group Collaboration to Address Needs for New Treatments in Orphan and Rare Disorders
“Rare Disease Day and events such as this help individuals and families living with rare diseases know that they are not alone and that there is a community raising awareness on their behalf. NORD is grateful for this opportunity to champion health equity for the rare disease community and help shine a light on their unique experiences and challenges,” said
“Rare Disease Day is an opportune moment to build awareness, consider our progress, and rally around what has yet to be done. Until the day rare disease becomes a global health priority, we must be relentlessly nimble, creative, resourceful, and collaborative in our efforts to improve the lives and care of the nearly one in 10 Americans and 400 million people worldwide living with rare conditions," added Craig Martin, CEO of Global Genes.
There are approximately 7,000 identified rare diseases affecting millions across the globe, including 30 million Americans. Only about 5% of the known rare diseases have approved treatments. The biopharmaceutical industry has made great progress, with more than 770 FDA-approved medicines since the enactment of the Orphan Drug Act in 1983. However, there is still much more work to be done. Partnering and collaborating with advocacy leaders and organizations will raise awareness and connect patients with appropriate providers.
“We are committed to making a meaningful impact on the lives of those living with rare diseases,” said
The ceremony will begin at approximately
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2020 and Catalyst's other filings with the
About Global Genes
Global Genes is a 501(c)(3) non-profit organization dedicated to eliminating the burdens and challenges of rare diseases for patients and families globally. In pursuit of our mission, we connect, empower, and inspire the rare disease community to stand up, stand out, and become more effective on their own behalf — helping to spur innovation, meet essential needs, build capacity and knowledge, and drive progress within and across rare diseases. We serve more than 400 million people around the globe and nearly one in 10 Americans affected by rare diseases. If you or someone you love has a rare disease or are searching for a diagnosis, contact Global Genes (www.globalgenes.org) at 949-248-RARE or visit our Resource Hub (https://resource-hub.globalgenes.org/home/)
For 70 years, the
About Conquer MG
Conquer MG offers help and hope to myasthenia gravis patients through their caring staff, and support groups in
Source: Catalyst Pharmaceuticals, Inc.